MAPT and Alzheimer disease: In recent years, despite the potential shown by Aβ and tau-targeted therapies in animal studies, several international Phase III clinical trials (e.g., Aducanumab, Semorinemab) have failed to meet their endpoints, highlighting the complexity of AD drug development and the challenges of clinical translation (Rostagno, 2022).